title: Mitomycin-C and vinblastine in advanced breast cancer.
abstract: Forty-two patients with metastatic breast cancer refractory to first-line therapies were treated with combination chemotherapy with mitomycin-C and vinblastine. A response to treatment was observed in 11 of 34 evaluable patients (32.3%), with 3 complete remissions (8.8%) and 8 partial remissions (23.5%). The median duration of response was 185+ days. The 12-month survival was 78% for responders, 48% for patients with stable disease and 0% for patients with progressive disease. The toxicity was acceptable with 20 episodes of moderate myelosuppression (58.8%) and 2 cases with congestive heart failure that responded to medical treatment. The MMC-VBL combination is an active regime for advanced breast cancer previously treated with antracyclines. This combination may be regarded as a standard second-line treatment for this type of tumor.
authors.affiliation: Department of Radiotherapy and Oncology, Valle Hebron Hospital, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Navarro
authors.forename: J
authors.initials: J
authors.lastname: Bellmunt
authors.forename: C
authors.initials: C
authors.lastname: Balañá
authors.forename: R
authors.initials: R
authors.lastname: Colomer
authors.forename: L
authors.initials: L
authors.lastname: Jolis
authors.forename: J M
authors.initials: JM
authors.lastname: del Campo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D014747:Vinblastine / Q000008:administration & dosage*
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D014747:Vinblastine